| Year |
Citation |
Score |
| 2020 |
Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Láng I, Rodeheffer RJ, Ewer MS, Suter T, et al. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. British Journal of Cancer. PMID 32203207 DOI: 10.1038/S41416-020-0786-X |
0.331 |
|
| 2020 |
Taarnhøj GA, Johansen C, Lindberg H, Basch E, Dueck A, Pappot H. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. Cancer Medicine. PMID 32154663 DOI: 10.1002/Cam4.2958 |
0.326 |
|
| 2019 |
Huberty J, Eckert R, Dueck A, Kosiorek H, Larkey L, Gowin K, Mesa R. Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research. Bmc Complementary and Alternative Medicine. 19: 121. PMID 31174535 DOI: 10.1186/S12906-019-2530-8 |
0.344 |
|
| 2019 |
Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, Mesa R, Petersen B, Farnoud N, Najfeld V, Rampal R, Dueck A, Hoffman R. Oral Idasanutlin in Patients with Polycythemia Vera. Blood. PMID 31167802 DOI: 10.1182/Blood.2018893545 |
0.313 |
|
| 2019 |
Solinas C, Silva PD, Venet D, Garaud S, Gu-Trantien C, Hilbers F, Azambuja Ed, Werner O, Peña LDl, Dueck A, Cosimo SD, Lang I, Huober J, Küemmel S, Denkert C, et al. Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial Cancer Research. 79: 3132-3132. DOI: 10.1158/1538-7445.Sabcs18-3132 |
0.32 |
|
| 2018 |
Macarulla Mercade T, Hendifar A, Li CP, Reni M, Riess H, Tempero MA, Dueck A, Botteman MF, Deshpande C, Lucas E, Oh DY. Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): A systematic literature review (SLR). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii253. PMID 32136565 DOI: 10.1093/Annonc/Mdy282.124 |
0.301 |
|
| 2018 |
Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, et al. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 30104176 DOI: 10.1016/J.Clml.2018.06.013 |
0.315 |
|
| 2018 |
Chumsri S, Sperinde J, Liu H, Gligorov J, Spano JP, Antoine M, Moreno-Aspita A, Tan W, Winslow J, Petropoulos CJ, Chenna A, Bates M, Weidler JM, Huang W, Dueck AC, et al. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29530935 DOI: 10.1158/1078-0432.Ccr-17-1864 |
0.327 |
|
| 2018 |
Sonbol MB, Hilal T, Dueck AC, Rosenthal AC, Conley CR, Kosiorek HE, Ginos BF, Gano KM, Nichols CS, Leis JF, Johnston PB, Habermann TM, Northfelt DW, Bergsagel PL, Inwards DJ, et al. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Leukemia & Lymphoma. 1-7. PMID 29320913 DOI: 10.1080/10428194.2017.1416368 |
0.305 |
|
| 2017 |
Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C, Camoriano J, Tibes R, Gano K, Palmer J, Mesa R. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leukemia Research. 60: 31-35. PMID 28646676 DOI: 10.1016/J.Leukres.2017.06.005 |
0.354 |
|
| 2017 |
Mascarenhas J, Lu M, Virtgaym E, Kosiorek H, Stal M, Sandy L, Orellana A, Xia L, Kremyanskaya M, Petersen B, Dueck A, Hoffman R. Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia Blood. 130: 254-254. DOI: 10.1182/Blood.V130.Suppl_1.254.254 |
0.326 |
|
| 2016 |
Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, et al. Associations between gender, disease features and symptom burden in the MPN population: An analysis by the MPN QOL International Working Group. Haematologica. PMID 27540137 DOI: 10.3324/Haematol.2016.149559 |
0.314 |
|
| 2015 |
Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, et al. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26598745 DOI: 10.1200/Jco.2015.62.9337 |
0.319 |
|
| 2015 |
Padrnos L, Dueck AC, Scherber R, Glassley P, Stigge R, Northfelt D, Mikhael J, Aguirre A, Bennett RM, Mesa RA. Quality of life and disease understanding: impact of attending a patient-centered cancer symposium. Cancer Medicine. 4: 800-7. PMID 25641947 DOI: 10.1002/Cam4.422 |
0.326 |
|
| 2014 |
Perez E, Holmes E, De Azambuja E, Dueck A, Baselga J, Viale G, Zujewski J, Goldhirsch A, Crescenzo R, Pritchard K, Wolff A, Jackisch C, Láng I, Untch M, Smith I, et al. Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc) Annals of Oncology. 25: v1. DOI: 10.1093/Annonc/Mdu438.2 |
0.329 |
|
| 2012 |
Perez E, Eckel-Passow J, Ballman K, Anderson S, Thompson E, Asmann Y, Jen J, Dueck A, Lingle W, Sledge G, Winer E, Gralow J, Jenkins R, Reinholz M. Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Pd10-04 |
0.338 |
|
| 2011 |
Scherber R, Dueck A, Kiladjian J, Slot S, Zweegman S, te Boekhorst P, Commandeur S, Schouten HC, Sackmann F, Fuentes AK, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, et al. The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs), Blood. 118: 3839-3839. DOI: 10.1182/Blood.V118.21.3839.3839 |
0.333 |
|
| 2011 |
Perez E, Ballman K, Reinholz M, Dueck A, Cheng H, Jenkins R, McCullough A, Chen B, Davidson N, Martino S, Kaufman P, Kutteh L, Sledge G, Geiger X, Ingle J, et al. PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd05-03 |
0.338 |
|
| 2010 |
Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA. Triple-negative breast cancers: unique clinical presentations and outcomes. Annals of Surgical Oncology. 17: 384-90. PMID 20853062 DOI: 10.1245/S10434-010-1260-4 |
0.303 |
|
| 2010 |
Scherber R, Barbui T, Vannucchi AM, Passamonti F, Barosi G, Rambaldi A, Ferarri ML, Dueck A, Tefferi A, Mesa RA. Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients Blood. 116: 5060-5060. DOI: 10.1182/Blood.V116.21.5060.5060 |
0.359 |
|
| 2010 |
Johansson PL, Andreasson B, Scherber R, Dueck A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients Blood. 116: 5053-5053. DOI: 10.1182/Blood.V116.21.5053.5053 |
0.356 |
|
| 2010 |
Scherber R, Dueck A, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients Blood. 116: 4095-4095. DOI: 10.1182/Blood.V116.21.4095.4095 |
0.334 |
|
| 2010 |
Perez E, Dueck A, Press M, Chen B, Jenkins R, Paik S, Kim C, Wiktor A, Meyer R, Ketterling R, Villalobos I, Finnigan M, Buyse M, Zujewski J, Shing M, et al. Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd10-02 |
0.304 |
|
| 2010 |
Halyard M, Dueck A, Pisansky T, McLaughlin S, Pierce L, Marks L, Solin L, Pockaj B, Perez E. Abstract P5-13-02: Impact of Adjuvant Trastuzumab on Local Regional Recurrence: Data from the NCCTG N9831 Study Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P5-13-02 |
0.322 |
|
| 2010 |
McCullough A, Dell'Orto P, Reinholz M, Gelber R, Dueck A, Russo L, Jenkins R, Andrighetto S, Chen B, Lingle W, Jackisch C, Perez E, Piccart-Gebhart M, Viale G. Abstract P3-10-36: Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-10-36 |
0.307 |
|
| 2010 |
Reinholz M, Dueck A, Wiktor A, Lingle W, Jenkins R, Davidson N, Martino S, Kaufman P, Kutteh L, Sledge G, Harris L, Gralow J, Geiger X, Perez E. Abstract P2-09-08: c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831 Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-09-08 |
0.338 |
|
| 2009 |
McCullough A, Dueck A, Chen B, Reinholz M, Wiktor A, Lingle W, Jenkins R, Perez E. HER-2 central confirmatory testing using ASCO/CAP guidelines for trastuzumab/lapatinib trial MCCR RC0639. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e11527. PMID 27964626 DOI: 10.1200/Jco.2009.27.15_Suppl.E11527 |
0.345 |
|
| 2009 |
Pockaj BA, Degnim AC, Boughey JC, Gray RJ, McLaughlin SA, Dueck AC, Perez EA, Halyard MY, Frost MH, Cheville AL, Sloan JA. Quality of life after breast cancer surgery: What have we learned and where should we go next? Journal of Surgical Oncology. 99: 447-55. PMID 19418493 DOI: 10.1002/Jso.21151 |
0.333 |
|
| 2009 |
Tenner K, Dueck A, Hillman D, Rowland K, Palmieri F, Suman V, Perez E. Meta-analysis of adverse event rates in 15 North Central Cancer Treatment Group phase II metastatic breast cancer clinical trials for the development of adverse event stopping rules. Cancer Research. 69: 6149. DOI: 10.1158/0008-5472.Sabcs-6149 |
0.331 |
|
| 2009 |
Dueck A, Hillman D, Liu H, Rowland K, Palmieri F, Suman V, Perez E. Comparison of binary efficacy endpoints in 11 North Central Cancer Treatment Group phase II metastatic breast cancer clinical trials. Cancer Research. 69: 6147. DOI: 10.1158/0008-5472.Sabcs-6147 |
0.36 |
|
| 2009 |
Moreno-Aspitia A, Anderson K, Reinholz M, Lipton A, Carney W, Dueck A, Lafky J, Fitch T, Hillman D, Perez E. Serum biomarker analysis in a phase II study of irinotecan in refractory metastatic breast cancer (MBC). Cancer Research. 69: 6074. DOI: 10.1158/0008-5472.Sabcs-6074 |
0.312 |
|
| 2009 |
Perez E, Reinholz M, Dueck A, Wiktor A, Lingle W, Davidson N, Martino S, Kaufman P, Kutteh L, Jenkins R. c-MYC amplification and correlation with patient outcome in early stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial N9831. Cancer Research. 69: 56. DOI: 10.1158/0008-5472.Sabcs-56 |
0.338 |
|
| 2009 |
Johnson B, Dueck A, Dakhil S, Stella P, Nikcevich D, Franco S, Wender D, Schaefer P, Colon-Otero G, Diekmann B, Perez E. Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: initial safety data from the Mayo Clinic cancer research consortium trial RC0639. Cancer Research. 69: 2109. DOI: 10.1158/0008-5472.Sabcs-2109 |
0.321 |
|
| 2009 |
Perez E, Reinholz M, Dueck A, Tenner K, Davidson N, Gralow J, Harris L, Kutteh L, Jenkins R, Chen B. Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial. Cancer Research. 69: 701-701. DOI: 10.1158/0008-5472.Sabcs-09-701 |
0.365 |
|
| 2009 |
Tan W, Dueck A, Flynn P, Steen P, Anderson D, Rowland K, Nothfeldt D, Lingle W, Copland J, Perez E. N0539 Phase II Trial of Fulvstrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor: A North Central Cancer Treatment Group Trial. Cancer Research. 69: 4096-4096. DOI: 10.1158/0008-5472.Sabcs-09-4096 |
0.37 |
|
| 2009 |
Palmieri F, Dueck A, Johnson D, Colon-Otero G, Diekmann B, Dakhil S, Franco S, Reinholz M, McCullough A, Rodeheffer R, Perez E. Cardiac Safety of Lapatinib Given Concurrently with Paclitaxel and Trastuzumab as Part of Adjuvant Therapy for Patients with HER2+ Breast Cancer: Pilot Data from the Mayo Clinic Cancer Research Consortium Trial RC0639. Cancer Research. 69: 3086-3086. DOI: 10.1158/0008-5472.Sabcs-09-3086 |
0.323 |
|
| 2009 |
Moreno-Aspitia A, Dueck A, Patel T, Hillman D, Tenner K, Dakhil S, Rowland K, McLaughlin S, Perez E. Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial. Cancer Research. 69: 2100-2100. DOI: 10.1158/0008-5472.Sabcs-09-2100 |
0.357 |
|
| 2008 |
Suman VJ, Dueck A, Sargent DJ. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Investigation. 26: 439-44. PMID 18568764 DOI: 10.1080/07357900801971057 |
0.302 |
|
| 2007 |
Revicki DA, Erickson PA, Sloan JA, Dueck A, Guess H, Santanello NC. Interpreting and reporting results based on patient-reported outcomes. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 10: S116-24. PMID 17995470 DOI: 10.1111/J.1524-4733.2007.00274.X |
0.327 |
|
| 2007 |
Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 110: 489-98. PMID 17592827 DOI: 10.1002/Cncr.22806 |
0.338 |
|
| 2007 |
Pockaj BA, Dueck A, Tenner K, Perez E. Impact of poor prognostic features on the surgical treatment of breast cancer in an intergroup adjuvant chemotherapic trial Journal of Clinical Oncology. 25: 612-612. DOI: 10.1200/Jco.2007.25.18_Suppl.612 |
0.352 |
|
| 2006 |
Garrison LP, Perez EA, Dueck A, Lalla D, Paton V, Lubeck D. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 6023. PMID 27954582 DOI: 10.1200/Jco.2006.24.18_Suppl.6023 |
0.344 |
|
| 2006 |
Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, Perez EA. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831 Journal of Clinical Oncology. 24: 523-523. DOI: 10.1200/Jco.2006.24.18_Suppl.523 |
0.352 |
|
| 2005 |
Dueck A, Lohr S. Robust estimation of multivariate covariance components. Biometrics. 61: 162-9. PMID 15737089 DOI: 10.1111/J.0006-341X.2005.030151.X |
0.553 |
|
| 2004 |
Sloan JA, Dueck A. Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical Trials Journal of Biopharmaceutical Statistics. 14: 73-96. PMID 15027501 DOI: 10.1081/Bip-120028507 |
0.336 |
|
| Show low-probability matches. |